Terms: = Prostate cancer AND PSA AND Clinical Outcome
296 results:
1. Salvage Radiotherapy PSMA PET/CT-guided in Men With psa Recurrence.
Tamburo M; Buffettino E; Pepe P; Marletta G; Pepe L; Cosentino S; Ippolito M; Pennisi M; Marletta F
Anticancer Res; 2024 May; 44(5):2205-2210. PubMed ID: 38677723
[TBL] [Abstract] [Full Text] [Related]
2. Combined Cabazitaxel and Carboplatin Treatment of Metastatic Castration Resistant prostate cancer Patients, With Innate or Acquired Resistance to Cabazitaxel Monotherapy.
van der Zande K; Tutuhatunewa-Louhanepessy RD; Hamberg P; Ras S; de Feijter JM; Dezentjé VO; Broeks A; Cornelissen S; Beeker A; van der Noort V; Zwart W; Bergman AM
Clin Genitourin Cancer; 2024 Apr; 22(2):445-453.e1. PubMed ID: 38246830
[TBL] [Abstract] [Full Text] [Related]
3. Early response monitoring during [
Neubauer MC; Nicolas GP; Bauman A; Fani M; Nitzsche E; Afshar-Oromieh A; Forrer F; Rentsch C; Stenner F; Templeton A; Schäfer N; Wild D; Chirindel A;
Eur J Nucl Med Mol Imaging; 2024 Mar; 51(4):1185-1193. PubMed ID: 38038755
[TBL] [Abstract] [Full Text] [Related]
4. A common germline variant in CYP11B1 is associated with adverse clinical outcome of treatment with abiraterone or enzalutamide.
Buck SAJ; Meertens M; van Ooijen FMF; Oomen-de Hoop E; de Jonge E; Coenen MJH; Bergman AM; Koolen SLW; de Wit R; Huitema ADR; van Schaik RHN; Mathijssen RHJ
Biomed Pharmacother; 2023 Dec; 169():115890. PubMed ID: 37988848
[TBL] [Abstract] [Full Text] [Related]
5. Early biochemical and radiographic response after one cycle of [
Cytawa W; Hendel R; Tomasik B; Weinzierl FX; Bley T; Jassem J; Schirbel A; Buck AK; Bundschuh RA; Hartrampf PE; Werner RA; Lapa C
Eur J Nucl Med Mol Imaging; 2023 Oct; 50(12):3765-3776. PubMed ID: 37474735
[TBL] [Abstract] [Full Text] [Related]
6. Extreme hypofractionated stereotactic radiotherapy for elderly prostate cancer patients: side effects preliminary analysis of a phase II trial.
Gregucci F; Carbonara R; Surgo A; Ciliberti MP; Curci D; Ciocia A; Branà L; Ludovico GM; Scarcia M; Portoghese F; Caliandro M; Ludovico E; Paulicelli E; Di Guglielmo FC; Bonaparte I; Fiorentino A
Radiol Med; 2023 Apr; 128(4):501-508. PubMed ID: 36952115
[TBL] [Abstract] [Full Text] [Related]
7. Randomized Phase II Cabazitaxel Dose Individualization and Neutropenia Prevention Trial in Patients with Metastatic Castration-Resistant prostate cancer.
Omlin A; Cathomas R; von Amsberg G; Reuter C; Feyerabend S; Loidl W; Boegemann M; Lorch A; Heidenreich A; Tsaur I; Larcher-Senn J; Buck SAJ; Mathijssen RHJ; Jaehde U; Gillessen S; Joerger M
Clin Cancer Res; 2023 May; 29(10):1887-1893. PubMed ID: 36917691
[TBL] [Abstract] [Full Text] [Related]
8. Impact of human telomerase reverse transcriptase peptide vaccine combined with androgen deprivation therapy and radiotherapy in de novo metastatic prostate cancer: Long-term clinical monitoring.
Lilleby W; Seierstad T; Inderberg EM; Hole KH
Int J Cancer; 2023 May; 152(10):2166-2173. PubMed ID: 36715014
[TBL] [Abstract] [Full Text] [Related]
9. Diagnostic and prognostic significance of tartrate-resistant acid phosphatase type 5b in newly diagnosed prostate cancer with bone metastasis: A real-world multi-institutional study.
Yamamichi G; Kato T; Yumiba S; Tomiyama E; Koh Y; Nakano K; Matsushita M; Hayashi Y; Ishizuya Y; Watabe T; Hatano K; Kawashima A; Ujike T; Ono Y; Takada T; Takada S; Imamura R; Nonomura N; Uemura M
Int J Urol; 2023 Jan; 30(1):70-76. PubMed ID: 36305578
[TBL] [Abstract] [Full Text] [Related]
10. Real-world comparison of Docetaxel versus new hormonal agents in combination with androgen-deprivation therapy in metastatic hormone-sensitive prostate cancer descrying psa Nadir ≤ 0.05 ng/ml as marker for treatment response.
Kafka M; Burtscher T; Fritz J; Schmitz M; Bektic J; Ladurner M; Horninger W; Heidegger I
World J Urol; 2023 Aug; 41(8):2043-2050. PubMed ID: 36287244
[TBL] [Abstract] [Full Text] [Related]
11. Response to [ 177 Lu]Lu-PSMA radioligand therapy in metastatic castration-resistant prostate cancer patients presenting with only lymph node metastases.
Zisser L; Yu J; Oszwald A; Wollenweber T; Kretschmer-Chott E; Grubmüller B; Kramer G; Shariat SF; Mitterhauser M; Vraka C; Hacker M; Haug AR; Rasul S
Nucl Med Commun; 2022 Nov; 43(11):1113-1120. PubMed ID: 36120814
[TBL] [Abstract] [Full Text] [Related]
12. The potential of cell-free and exosomal microRNAs as biomarkers in liquid biopsy in patients with prostate cancer.
de Nóbrega M; Dos Reis MB; Pereira ÉR; de Souza MF; de Syllos Cólus IM
J Cancer Res Clin Oncol; 2022 Oct; 148(10):2893-2910. PubMed ID: 35922694
[TBL] [Abstract] [Full Text] [Related]
13. Comparison of circulating tumor cells and AR-V7 as clinical biomarker in metastatic castration-resistant prostate cancer patients.
Schlack K; Seitzer K; Wüstmann N; Humberg V; Grundmann N; Steinestel J; Tiedje D; Rahbar K; Krabbe LM; Bögemann M; Schrader AJ; Bernemann C
Sci Rep; 2022 Jul; 12(1):11846. PubMed ID: 35831403
[TBL] [Abstract] [Full Text] [Related]
14. clinical outcome of Salvage Radiotherapy for Locoregional clinical Recurrence After Radical prostatectomy.
Lee SU; Cho KH; Kim JH; Kim YS; Nam TK; Kim JS; Cho J; Choi SH; Shim SJ; Kim JH; Chang AR
Technol Cancer Res Treat; 2021; 20():15330338211041212. PubMed ID: 34806469
[No Abstract] [Full Text] [Related]
15.
Metser U; Ortega C; Hussey D; Chan R; Berlin A; Finelli A; Veit-Haibach P
Curr Oncol; 2021 Aug; 28(5):3251-3258. PubMed ID: 34449586
[TBL] [Abstract] [Full Text] [Related]
16. Utility of radiomic zones for risk classification and clinical outcome predictions using supervised machine learning during simultaneous
Tu SJ; Tran VT; Teo JM; Chong WC; Tseng JR
Med Phys; 2021 Sep; 48(9):5192-5201. PubMed ID: 34214211
[TBL] [Abstract] [Full Text] [Related]
17. Does greater patient involvement in healthcare decision-making affect malpractice complaints? A large case vignette survey.
Birkeland S; Bismark M; Barry MJ; Möller S
PLoS One; 2021; 16(7):e0254052. PubMed ID: 34214136
[TBL] [Abstract] [Full Text] [Related]
18. Active surveillance in males with low- to intermediate-risk localized prostate cancer: A modern prospective cohort study.
Rakauskas A; Tawadros T; Lucca I; Herrera F; Bourhis J; Burruni R; Gomes MN; Codeluppi C; Jolliet L; La Rosa S; Meuwly JY; Jichlinski P; Berthold D; Valerio M
Investig Clin Urol; 2021 Jul; 62(4):416-422. PubMed ID: 34190436
[TBL] [Abstract] [Full Text] [Related]
19. Distinct Response to Platinum-Based Chemotherapy among Patients with Metastatic Castration-Resistant prostate cancer Harboring Alterations in Genes Involved in Homologous Recombination.
Fan L; Fei X; Zhu Y; Chi C; Pan J; Sha J; Xin Z; Gong Y; Du X; Wang Y; Dong B; Xue W
J Urol; 2021 Sep; 206(3):630-637. PubMed ID: 33904759
[TBL] [Abstract] [Full Text] [Related]
20. [68Ga]Ga-PSMA-11 PET-CT: Local preliminary experience in prostate cancer biochemical recurrence patients.
Carvalho J; Nunes P; Da Silva ET; Silva R; Lima J; Quaresma V; Figueiredo A
Arch Ital Urol Androl; 2021 Mar; 93(1):21-25. PubMed ID: 33754603
[TBL] [Abstract] [Full Text] [Related]
[Next]